Auxilium Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference

MALVERN, PA, Nov 02 (MARKET WIRE) --
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that
executive management will participate in the Oppenheimer Healthcare
Conference to be held November 3 - 4, 2009 at the Waldorf Astoria in New
York City. Mr. Armando Anido, Chief Executive Officer and President, is
scheduled to present an overview of the Company and its product pipeline
at 10:50 a.m. EST on Wednesday, November 4, 2009.

To listen to the audio web cast of the presentation during or after the
event, please visit: http://www.auxilium.com. The replay will be available
for ninety days after the event.

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company
with a focus on developing and marketing to urologists, endocrinologists,
orthopedists and select primary care physicians. Auxilium markets
Testim(R) 1%, a topical testosterone gel, for the treatment of
hypogonadism through its approximately 190-person sales and marketing
team. Auxilium has five projects in clinical development. XIAFLEX(TM)
(collagenase clostridium histolyticum), formerly referred to as AA4500,
has completed phase III clinical trials for the treatment of Dupuytren's
disease, and the biologics license application is under review at the FDA
for the treatment of Dupuytren's disease. XIAFLEX is in phase IIb of
development for the treatment of Peyronie's disease and is in phase II of
development for treatment of Frozen Shoulder syndrome (Adhesive
Capsulitis). Auxilium's transmucosal film product candidate for the
treatment of overactive bladder (AA4010) and its fentanyl pain product
using its transmucosal delivery system are in phase I of development. The
Company is currently seeking a partner to further develop these product
candidates. Auxilium has rights to additional pain products and products
for hormone replacement and urologic disease using its transmucosal film
delivery system. Auxilium also has options to all indications using
XIAFLEX for non-topical formulations. For additional information, visit
http://www.auxilium.com.

Safe Harbor Statement

This release contains "forward-looking-statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to present at the Oppenheimer 20th
Annual Healthcare Conference, and products in development for the
treatment of Dupuytren's contracture, Peyronie's disease and Frozen
Shoulder Syndrome and for pain, hormone replacement and urologic disease.
All statements other than statements of historical facts contained in
this release, including but not limited to, statements regarding future
expectations, plans and prospects for the Company, statements regarding
forward-looking financial information and other statements containing the
words "believe," "may," "could," "will," "estimate," "continue,"
"anticipate," "intend," "should," "plan," "expect," and similar
expressions, as they relate to the Company, constitute forward-looking
statements. Actual results may differ materially from those reflected in
these forward-looking statements due to various factors, including
further evaluation of clinical data, results of clinical trials,
decisions by regulatory authorities as to whether and when to approve
drug applications, and general financial, economic, regulatory and
political conditions affecting the biotechnology and pharmaceutical
industries and those discussed in the Company's Annual Report on Form 10-K
for the year ended December 31, 2008 and the Company's Quarterly Report on
Form 10-Q for the period ended June 30, 2009 under the heading "Risk
Factors," which are on file with the Securities and Exchange Commission
(the "SEC") and may be accessed electronically by means of the SEC's home
page on the Internet at http://www.sec.gov or by means of Auxilium's home
page on the Internet at http://www.Auxilium.com under the heading
"Investor Relations -- SEC Filings." There may be additional risks that
Auxilium does not presently know or that Auxilium currently believes are
immaterial which could also cause actual results to differ from those
contained in the forward-looking statements. Given these risks and
uncertainties, any or all of these forward-looking statements may prove
to be incorrect. Therefore, you should not rely on any such factors or
forward-looking statements.

In addition, forward-looking statements provide the Company's
expectations, plans or forecasts of future events and views as of the
date of this release. The Company anticipates that subsequent events and
developments will cause the Company's assessments to change. However,
while the Company may elect to update these forward-looking statements at
some point in the future, the Company specifically disclaims any
obligation to do so. These forward-looking statements should not be
relied upon as representing the Company's assessments as of any date
subsequent to the date of this release.

For More Information, Contact:

James E. Fickenscher / CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
Email Contact

William Q. Sargent, Jr. / V.P., IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-